State Street SPDR S&P Biotech ETF
274 hedge funds and large institutions have $2.17B invested in State Street SPDR S&P Biotech ETF in 2016 Q4 according to their latest regulatory filings, with 83 funds opening new positions, 75 increasing their positions, 72 reducing their positions, and 28 closing their positions.
196% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 28
21% more funds holding
Funds holding: 227 → 274 (+47)
4% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 72
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
28% less call options, than puts
Call options by funds: $793M | Put options by funds: $1.1B
29.78% less ownership
Funds ownership: 118.69% → 88.91% (-30%)
30% less capital invested
Capital invested by funds: $3.11B → $2.17B (-$946M)
Top Buyers
Top Sellers
| 1 |
Citigroup
New York
|
-$275M |
| 2 |
Goldman Sachs
New York
|
-$258M |
| 3 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$99.4M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$95.3M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$92.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
301
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$13K | -240 | Closed |
|
302
Mariner
Overland Park,
Kansas
| – | -$6K | -93 | Closed |
|
|
MWP
303
MYCIO Wealth Partners
Philadelphia,
Pennsylvania
| – | -$6K | -85 | Closed |
|
|
ACM
304
Argentus Capital Management
Dallas,
Texas
| – | -$3K | -41 | Closed |
|
XBI Hedge Fund Activity: Q4 2016 in Review
274 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q4 2016, worth a combined $2.17B — down 30% from $3.11B a quarter earlier.
Buyers outnumbered sellers: 83 funds opened new XBI positions and 28 closed out — a net gain of 55 holders — while 75 added to existing stakes and 72 trimmed.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $75.5M. The largest seller was Citigroup, cutting an estimated $275M.
- 274 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q4 2016, up from 227 in Q3 2016.
- Funds reported $2.17B of State Street SPDR S&P Biotech ETF stock for Q4 2016, down 30% quarter-over-quarter.
- 83 funds opened new State Street SPDR S&P Biotech ETF positions in Q4 2016 and 28 closed out, a net change of +55 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q4 2016 was Suvretta Capital Management, an estimated $75.5M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q4 2016 was Citigroup, an estimated $275M sold.
Based on aggregated 13F filings for Q4 2016.